hBD3-3 M1
General Information
DCTPep ID DCTPep01164
Peptide Name hBD3-3 M1
Sequence GKCSTRGRKCMRRKK
Sequence Length 15
UniProt ID Not available
PubChem CID Not available
Origin Not available
Type Synthetic peptide
Classification
ACP
Activity Information
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target Not available
Affinity Not available
Mechanism Not available
Structure Information
PDB ID Not available
Predicted Structure DCTPep01164
(Please note that there is the predicted structure, predicted by AlphaFold)
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Free
Other Modification None
Chiral L
Physicochemical Information
Formula C70H135N31O18S3
Absent amino acids ADEFHILNPQVWY
Theoretical pI 11.58
Acidic residues 0
Basic residues 8
Polar residues 6
Molecular weight (Average) 1795.22
Molecular weight (Monoisotopic) 1793.98
Common amino acids KR
Net charge 8
Instability index (II) 52.91
Aliphatic index 0.00
Grand average of hydropathicity (GRAVY) -1.933
Half Life
30 hours (mammalian reticulocytes, in vitro).
>20 hours (yeast, in vivo).
>10 hours (Escherichia coli, in vivo).
Extinction coefficients
Ext. coefficient 125
Abs 0.1% (=1 g/l) 0.070, assuming all pairs of Cys residues form cystines
Ext. coefficient 0
Abs 0.1% (=1 g/l) 0.000, assuming all Cys residues are reduced
Amino acid distribution
Literature Information
Literature 1
Pubmed ID Not available
Title Not available
Doi Not available
Year Not available
Patent
Patent ID EP3111951B1
Patent Title Anticancer Functional Peptide for the Treatment of Breast Cancer
Other Iinformation Granted Patent; Family: 9s / 9ex; Family Jurisdictions: KR, US, WO, ES, EP; Legal Status: Active; Application No: 16736753; Filed: Mar 3, 2016; Published: Dec 11, 2019; Earliest Priority: Mar 26, 2015; Granted: Dec 11, 2019
Other Published ID EP3111951A4 EP3111951B1 ES2773755T3 KR101693533B1 KR20160115314A US2017042963A1 US9993519B2 WO2016153185A1